1. Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): A randomized, double-blind, placebo-controlled trial. (September 2017) Authors: Gouni-Berthold, I.; Alexander, V.; Digenio, A.; DuFour, R.; Steinhagen-Thiessen, E.; Martin, S.; Moriarty, P.; Hughes, S.; Jones, R.; Witztum, J.L.; Gaudet, D. Journal: Atherosclerosis Issue: Volume 28(2017) Page Start: e1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Atherogenic lipoprotein(A) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation. (December 2020) Authors: Schnitzler, J.G.; Hoogeveen, R.M.; Ali, L.; Prange, K.; Weeghel, M.V.; Versloot, M.; Waissi, F.; Houtkooper, R.; De Kleijn, D.P.V.; De Winther, M.; Koschinsky, M.; Tsimikas, S.; Witztum, J.L.; Stroes, E.; Kroon, J. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Defining the mechanism of lipoprotein(a) [Lp(a)] lowering by alirocumab in transgenic mouse models. (September 2016) Authors: Yeang, C.; Miu, P.; Green, S.; Yang, X.; Hung, M.Y.; Witztum, J.L.; Tsimikas, S. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effects of patient characteristics on volanesorsen efficacy: Subgroup analysis of approach. (August 2022) Authors: Witztum, J.L.; Gaudet, D.; Freedman, S.; Alexander, V.J.; Arca, M.; Stroes, E.S.; Bergeron, J.; Soran, H.; Civeira, F.; Tsimikas, S.; Blom, D.J.; Bruckert, E. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Expression of E06, a natural monoclonal antibody targeted to oxidized phospholipids (OXPL), attenuates the progression of aortic sclerosis in aged hyperlipidemic mice. (September 2016) Authors: Yeang, C.; Hung, M.Y.; Pattison, J.; Bowden, K.; Dalton, N.; Peterson, K.L.; Witztum, J.L.; Tsimikas, S.; Que, X. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e229 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Interventional hepatic ApoC-III knockdown improves atherosclerotic plaque stability and remodeling via lowering remnant lipoproteins. (August 2021) Authors: Gordts, P.; Ramms, B.; Pessentheiner, A.; Sun, X.; Ducasa, G.M.; Tsimikas, S.; Witztum, J.L. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. ISIS-ANGPTL3RX, an antisense inhibitor to angiopoietin-like 3, reduces plasma lipid levels in mouse models and in healthy human volunteers. Issue 1 (July 2015) Authors: Brandt, T.A.; Lee, R.G.; Digenio, A.; Graham, M.G.; Crooke, R.M.; Hughes, S.G.; Singleton, W.; Witztum, J.L.; Tsimikas, S. Journal: Atherosclerosis Issue: Volume 241:Issue 1(2015) Page Start: e30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Natural temporal variability in Lp(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx antisense oligonucleotide clinical trials. (September 2016) Authors: Viney, N.J.; Marcovina, S.; Tami, J.; Xia, S.; Witztum, J.L.; Tsimikas, S. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Novel method for quantification of lipoprotein(a)-cholesterol: Implications for improving accuracy of LDL-C measurements. (August 2021) Authors: Yeang, C.; Su, F.; Witztum, J.L.; Tsimikas, S. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Plasma apolipoprotein CIII levels and incident coronary artery disease risk: The EPIC-Norfolk prospective population study. (September 2016) Authors: van Capelleveen, J.; Moens, S.J. Bernelot; Yang, X.; Wareham, N.T.; Khaw, K.T.; Stroes, E.S.G.; Witztum, J.L.; Hovingh, G.K.; Boekholdt, S.M.; Tsimikas, S. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e100 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗